Skip to main content

Advertisement

SpringerLink
Log in

Points to Consider Regarding Risk-Reducing Mastectomy in High-, Moderate-, and Low-Penetrance Gene Carriers

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Risk-reducing mastectomy is considered a safe and effective surgical procedure in high-risk individuals with BRCA1/2 germline mutations. Multigene panels identify women with alterations in breast cancer susceptibility genes other than BRCA1/2. International guidelines classify these genes as high-, moderate-, and low-penetrance based on their associated relative risk for breast cancer. Classification of specific genes is not always concordant among guidelines, and the indications for risk-reducing mastectomy are not defined. In this opinion paper, we review some considerations to clarify these controversial points.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Daly MB, Pal T, Berry MP, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:77–102.

    Article  CAS  Google Scholar 

  2. Burstein HJ, Curigliano G, Thürlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer. Ann Oncol. 2021;32:1216–35.

    Article  CAS  Google Scholar 

  3. Tung NM, Boughey JC, Pierce LJ, et al. Management of hereditary breast cancer: American society of clinical oncology, American society for radiation oncology, and society of surgical oncology guideline. J Clin Oncol. 2020;38:2080–106.

    Article  CAS  Google Scholar 

  4. Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105:812–22.

    Article  CAS  Google Scholar 

  5. Blair VR, McLeod M, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020;21:e386–97.

    Article  CAS  Google Scholar 

  6. Corso G, Figueiredo J, La Vecchia C, et al. Hereditary lobular breast cancer with an emphasis on E-cadherin genetic defect. J Med Genet. 2018;55:431–41.

    Article  CAS  Google Scholar 

  7. Ro V, McGuinness JE, Guo B, et al. Association between genetic testing for hereditary breast cancer and contralateral prophylactic mastectomy among multiethnic women diagnosed with early-stage breast cancer. JCO Oncol Pract. 2022;18(4):e472–83.

Download references

Acknowledgments

The preparation of this study was partially supported by a) Italian Ministry of Health with Ricerca Corrente and 5 x 1000 funds, b) NIH/NCI Cancer Center Support Grant P30 CQA008748, and c) Breast Cancer Research Foundation.

Author information

Authors and Affiliations

  1. Division of Breast Surgery, IEO European Institute of Oncology, IRCCS, via Ripamonti 435, 20141, Milan, Italy

    Giovanni Corso MD, PhD

  2. Department of Oncology and Hemato-Oncology, University of Milan, 20122, Milan, Italy

    Giovanni Corso MD, PhD & Virgilio Sacchini MD

  3. European Cancer Prevention Organization (ECP), 20141, Milan, Italy

    Giovanni Corso MD, PhD

  4. Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA

    Mark E. Robson MD

  5. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA

    Virgilio Sacchini MD

Authors
  1. Giovanni Corso MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark E. Robson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Virgilio Sacchini MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Corso MD, PhD.

Ethics declarations

Disclosures

MR received honoraria from Research to Practice, Intellisphere Physicians’ Education Resource, and MyMedEd; consulting/advisor from Artios Pharma (uncompensared), AstraZeneca (uncompensated), Change Healthcare, Daiichi-Sankyo (uncompensated), Epic Sciences (uncompensated), Merck (uncompensated), Pfizer (uncompensated), Tempus Lab (uncompensated), Zenith Pharma (uncompensated). Research funding from AstraZeneca (Institution), Merck (Institution), and Pfizer (institution). GC and VS have not disclosure to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Corso, G., Robson, M.E. & Sacchini, V. Points to Consider Regarding Risk-Reducing Mastectomy in High-, Moderate-, and Low-Penetrance Gene Carriers. Ann Surg Oncol 29, 5821–5825 (2022). https://doi.org/10.1245/s10434-022-11913-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-11913-6

Search

Navigation